Effects of Aging on Primary and Secondary Vaccine Responses

Summary

The purpose of this study is to use an existing, unique clinical cohort: the longitudinal cohort of younger (21-40 years) and elderly (\>65 years) subjects whose yearly influenza vaccine responses have been studied extensively since 2007, to gain molecular and cellular mechanistic insights into the impaired vaccine responses in the elderly.

Conditions

• Influenza
• Hepatitis A
• Typhoid
• Healthy Adults

Interventions

BIOLOGICAL

Fluzone® quadrivalent

IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by intramuscular (IM) injection into the deltoid muscle.

BIOLOGICAL

Fluzone High Dose

High Dose IIV3 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

BIOLOGICAL

Fluad

Fluad vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

BIOLOGICAL

Vaqta

Vaqta vaccine will be administered as a 1 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

BIOLOGICAL

Typhim Vi

Typhim Vi vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

BIOLOGICAL

Vivotif

One capsule is to be swallowed approximately 1 hour before a meal with a cold or luke-warm \[temperature not to exceed body temperature, e.g., 37 °C (98.6 °F)\] drink on alternate days, e.g., days 1, 3, 5 and 7.

Sponsors & Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID)

  collaborator NIH

• Stanford University

  lead OTHER

Principal Investigators

• Scott Boyd, MD, PhD · Stanford School of Medicine, Dept. of Pathology

• Cornelia Dekker, MD · Stanford School of Medicine, Dept. of Pediatrics

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2017-09-19

Primary Completion

2023-12-31

Completion

2023-12-31

FDA Drug

Yes

Countries

• United States

Study Locations